Garage Sale Auctions: Over 700 lots are available for a LIMITED TIME ONLY...starting at just $1! Click here to bid now!

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Oncology Homepage

Researchers develop AI approach for high-risk clinical tumor volumes Assisting low- and middle-income countries that lack contouring expertise

Dr. Benjamin Movsas American Radium Society Names president-elect

Tennessee governor vetoes state employee proton therapy coverage Would require PT to be covered under the same aggregate amount as IMRT

European medical center first to perform linac-based MR-guided RT using on-table adaptation Made possible with ViewRay's MRIdian Linac

Hospital in Italy performs radiosurgery with Brainlab's Elements Spine SRS software Automatically plans treatments for complex parts of the body

AI approach used to study Mars now assessing tumor response to therapies Could reduce sample sizes and accelerate process for approval of cancer therapies

Thermal imaging in development could provide real-time ablation views Taking guesswork and additional imaging out of the equation

PPI to purchase Elekta MR-linac systems for £25 million Will install at five cancer centers across the UK

Dr. Nancy P. Mendenhall Medical Director of UF Health Proton Therapy selected by University of Florida as 2018 Clinical Science Researcher of the Year

ViewRay showcases enhancements to MRIdian Linac system at ESTRO Will offer MR pulse sequencing capabilities

Proton therapy room
Courtesy of Penn Medicine

ASTRO releases updated insurance coverage recommendations for proton therapy

by Lauren Dubinsky , Senior Reporter
In light of new research, the American Society for Radiation Oncology recently made updates to its insurance coverage guidelines for proton beam therapy.

"This policy update reflects the most current knowledge regarding which patients will benefit from — and therefore should have access to — this cutting-edge treatment," Dr. David C. Beyer, ASTRO Chair, said in a statement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

The original policy was issued in 2014 when the technology was still in its infancy. The updated Proton Beam Therapy Model Policy provides guidance on the clinical indications that are appropriate for treatment and should be covered by Medicare, Medicaid and private insurance.

The clinical indications are divided into two categories, based on evidence from published clinical data and current Medicare coverage. Coverage is recommended for Group 1, but it's only recommended for Group 2 if additional requirements are met.

For Group 1, five additions and one modification were made to the original guidelines:

  • Malignant and benign primary central nervous system tumors

  • Advanced and/or unresectable head and neck cancers

  • Cancers of the paranasal sinuses and other accessory sinuses

  • Nonmetastatic retroperitoneal sarcomas

  • Reirradiation cases where cumulative critical structure dose would exceed tolerance dose

  • Hepatocellular cancer is no longer required to be treated in a hypofractionated regimen

For Group 2, coverage is recommended if the patient is enrolled in an Institutional Research Board-approved study or a multi-institutional registry that adheres to Medicare's Coverage with Evidence Development (CED) requirements.

However, evidence is accumulating for these indications that may push them into Group 1 in the future. Even though the policy states that no indications are considered inappropriate for CED, it does specify several systems for Group 2 indications:

  • Non-T4 and resectable head and neck cancers (previously it was all head and neck malignancies)

  • Nonmetastatic prostate cancer (previously it was grouped with genitourinary carcinomas)

Beyer said that ASTRO is committed to developing evidence to identify new areas where proton therapy may be beneficial as well as situations where it might not be.

ASTRO's Payer Relations Subcommittee developed the update guidelines, which were reviewed by the Health Policy Council and approved by the Board of Directors last month.

Back to HCB News
  Pages: 1

Oncology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.